IL-4Rα aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment

References

• Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009;113:3546–52.
   PubMed Web of Science ®Google Scholar
• Lou Y, Liu C, Lizée G, et al. Antitumor activity mediated by CpG: the route of administration is critical. J Immunother 2001;34:279–88.
   Web of Science ®Google Scholar
• Wang X, Dong H, Li Q, et al. Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma. Oncoimmunology 2015;4:e1027471.
   PubMed Web of Science ®Google Scholar
• Pyzer AR, Cole L, Rosenblatt J, Avigan DE. Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Int J Cancer 2016;139:1915–26.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang J, Chen S, et al. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 2011;74:188–96.
   PubMed Web of Science ®Google Scholar
• Shirota Y, Shirota H, Klinman DM. Intra-tumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 2012;188:1592–9.
   PubMed Web of Science ®Google Scholar
• Supaporn S, Masaharu U. Effect of a PEG lipid (DSPE-PEG2000) and freeze-thawing process on phospholipid vesicle size and lamellarity. Colloid Phlym Sci 2004;282:753–60.
   Web of Science ®Google Scholar
• Xu Y, Shi L, Ddeng YH. Effect of polyethylene glycol-lipid derivatives on the stability of grafted liposomes. Yao Xue Xue Bao 2011;46:1178–86. [Article in Chinese]
   PubMedGoogle Scholar
• Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 2009;1788:2259–66.
   PubMed Web of Science ®Google Scholar
• Du HY, Xia SY, Song HF, et al. Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells. Acta Pharmacol Sin 2007;28:1637–44.
   PubMed Web of Science ®Google Scholar
• Du HY, Dong LH, Zhao BJ, et al. Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice. Acta Pharmacol Sin 2012;33:1047–54.
   PubMed Web of Science ®Google Scholar
• Wang X, Ge H, Wang Q, et al. Preparation optimization of cationic liposome-siRNA complexes and therapeutic research on prostate cancer. Chin Pharm J 2014;49:669–73.
   Google Scholar
• Roth F, De La Fuente AC, Vella JL, et al. Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 2012;72:1373–83.
   PubMed Web of Science ®Google Scholar
• Fu J, Cheng L, Wang Y, et al. The RNA-binding protein RBPMS1 represses AP-1 signaling and regulates breast cancer cell proliferation and migration. Biochim Biophys Acta 2015;1853:1–13.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162–74.
   PubMed Web of Science ®Google Scholar
• Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol 2013;91:493–502.
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Finke J, Montero AJ. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 2014;41:174–84.
   PubMed Web of Science ®Google Scholar
• Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008;181:4666–75.
   PubMed Web of Science ®Google Scholar
• Rigamonti N, Capuano G, Ricupito A, et al. Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. Clin Cancer Res 2011;17:1012–23.
   PubMed Web of Science ®Google Scholar
• Shen L, Sundstedt A, Ciesielski M, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 2015;3:136–48.
   PubMed Web of Science ®Google Scholar
• Finke J, Ko J, Rini B, et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011;11:856–61.
   PubMed Web of Science ®Google Scholar
• Chen J, Deng C, Shi Q, et al. CpG oligodeoxynucleotide induces bone marrow precursor cells into myeloid-derived suppressor cells. Mol Med Rep 2013;8:1149–54.
   PubMed Web of Science ®Google Scholar
• Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010;40:2969–75.
   PubMed Web of Science ®Google Scholar
• Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439–49.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang B, Li D, et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One 2010;5:e8922.
   PubMed Web of Science ®Google Scholar
• Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004;173:3844–54.
   PubMed Web of Science ®Google Scholar
• Masuda Y, Inoue H, Ohta H, et al. Oral administration of soluble β-glucans extracted from Grifola frondosa induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice. Int J Cancer 2013;133:108–19.
   PubMed Web of Science ®Google Scholar
• Yu J, Wang Y, Yan F, et al. Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol 2014;193:2574–86.
   PubMed Web of Science ®Google Scholar